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Chapter 1 
 
General Introduction 
 
1.1 Mitral regurgitation and mitral valve repair 
Mitral regurgitation (MR) due to degenerative mitral valve disease is the most common 
heart disease in dogs, accounting for 75 to 80% of cardiac disease in dogs1. Signs of 
progressive MR may be challenging to control with medication alone. The median survival 
time for dogs with severe MR is 6 to 7 months2, 3. Mitral valve repair (MVR) is an 
alternative treatment option for MR and has demonstrated results superior to mitral valve 
replacement in humans 4, 5, 6. Surgical intervention to correct MR7, 8, 9 and long-term survival 
following valve replacement8 has been reported in dogs. However, the primary issue 
associated with mitral valve replacement is the subsequent need for life-long antithrombotic 
treatment, which is not required following MVR8. At present, the long-term outcome in dogs 
after MVR is poorly documented7, 9. Griffith et al concluded that it is difficult to succeed 
mitral valve repair of the small breed dogs. We succeeded to improve the success rate of 
mitral valve repair and perform mitral valve repair to small breed dogs consistently. 
However, the success rate of mitral valve repair is about 90 % that is not enough.  
Cardiac surgery with cardiopulmonary bypass (CPB) is well known to cause systemic 
inflammatory response syndrome (SIRS) in humans, characterized by the activation of 
cytokines, the complement cascade, free radicals, and nitric oxide.10, 11, 12 This so-called 
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post-pump inflammatory response may induce postoperative multi-system dysfunction in the 
renal, pulmonary, nervous, hepatic, and myocardial systems,13, 14, 15 which may increase the 
morbidity and mortality of cardiac surgery16. Therefore, it may be difficult for the dogs with 
severe systemic organ dysfunction to receive mitral valve repair needing cardiopulmonary 
bypass.  
 
1.2 Transcatheter valve replacement 
Since 2002,17 the less invasive transcatheter aortic valve implantation (TAVI) has been 
introduced for inoperable and high-risk patients. Recently, with technological advancements, 
the clinical application of TAVI has extended to intermediate-risk patients.18 TAVI is 
expected to evolve further and become more commonly used in the future. Transcatheter 
valve replacement of atrioventricular valves (mitral valve and tricuspid valve) such as valve 
in the mitral ring implantation or in annuloplasty ring implantation were clinically 
performed to the re-operative patient. Transcatheter replacement of the native 
atrioventricular valves is not a clinical reality yet due to several technical problems arising 
from the large size and irregular shape of the annulus, potentially resulting in complications 
with prosthesis fixation and perivalvular leak. Nonetheless, two acute animal studies have 
been published pioneering feasibility of transcatheter valve implantation in the native mitral 
and tricuspid position using a custom-made nitinol stent19, 20 However, using a bioprosthetic 
valve for TVR has certain disadvantages, since it undergoes progressive degeneration and 
calcification as it contains no living cells.21, 22 To overcome these limitations, living heart 
valves—created by tissue engineering—have been under development. Some heart valves 
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created by tissue engineering have been successfully implanted in animals.23, 24 However, 
these valves require complicated cell management protocols with cell culture in bioreactors 
under strictly sterile conditions; this procedure is time-consuming and expensive. 
1.3 Concept of in vivo tissue engineered heart valve 
We have previously developed autologous prosthetic tissues by using the “in-body tissue 
architecture (IBTA)” technology, which is a novel and practical approach for regenerative 
medicine based on the tissue encapsulation phenomenon of foreign materials in living 
bodies.9 This technology involves the use of living bodies as a reactor, and does not need 
expensive facilities or complicated manipulations. We have reported the construction of 
completely autologous tri-leaflet heart valves, named Biovalves, prepared using this 
technology,25-29 which may resolve the abovementioned problems encountered with 
bioprosthetic valves. (Fig.1) In fact, Biovalves have been demonstrated to have excellent 
valve function and histological changes when implanted as a pulmonary valve in a beagle 
model and an aortic valve in a goat model.30, 31 In these Biovalves, leaflet formation occurs 
by tissue ingrowth into small apertures in the preparation molds from the connective tissues 
surrounding the molds. During the encapsulation process, the conduit portion of the 
Biovalve is completely formed within approximately 4 weeks of embedding, similar to the 
Biotubes, which are autologous vascular grafts from IBTA. Being created Biovalves with 
stents for dogs, it may become possible to treat mitral regurgitation with transcatheter mitral 
valve replacement.   
 
 
 4 
1.4 Research aims 
Therefore, the aim of this thesis was to investigate the effectiveness and problems of the 
existing treatment (mitral valve repair undergoing cardiopulmonary bypass) and develop a 
novel treatment device for canine chronic mitral valve disease 
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Chapter 2 
Section 1 
Long-term outcome in dogs undergoing mitral valve repair with 
suture annuloplasty and chordaw tendinae replacement 
 
2.1.1 Introduction 
Mitral regurgitation (MR) due to degenerative mitral valve disease is the most 
common heart disease in dogs, accounting for 75–80% of cardiac disease in dogs1. Signs of 
progressive mitral regurgitation may be challenging to control with medication alone. The 
median survival time for dogs with severe MR is 6–7 months2, 3. 
Mitral valve repair (MVR) developed as an alternative treatment option for MR and 
has demonstrated results superior to mitral valve replacement in humans4, 5, 6. Surgical 
intervention to correct MR7, 8, 9 and long-term survival following valve replacement8 have 
been reported in dogs. However, the primary issue associated with mitral valve replacement 
is the subsequent need for life-long antithrombotic treatment, which is not required 
following MVR.8 At present, the long-term outcome in dogs after MVR is poorly 
documented7, 9. We present the long-term outcome of 3 small-breed dogs (body weight < 5 
kg) after MVR.  
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2.1.2 Animals, materials and methods 
Case 1: An 8-year-old male Maltese weighing 2.4 kg with respiratory distress and cyanosis 
was referred to the clinic due to pulmonary oedema caused by MR. Clinical examination 
revealed a grade IV systolic murmur with maximum intensity over the left cardiac apex. The 
plasma concentration of atrial natriuretic peptide (ANP) was 368 pg/mL (reference range < 
100 pg/mL) 32, 33. A thoracic radiograph showed mild cardiac enlargement with a vertebral 
heart size (VHS) of 11.0 vertebral lengths (v) and pulmonary oedema. Two-dimensional 
echocardiography showed mitral valve prolapse and ruptured chordae tendineae. The 
fractional shortening was 50%. The normalised left ventricular end diastolic diameter was 
2.39 (reference range < 1.85 34). The left atrium-to-aorta ratio (LA/Ao) in the right 
parasternal short axis at the level of the heart base was 2.3 (reference range 0.52-1.1335). 
Colour flow Doppler examination revealed severe MR.  
Pulmonary oedema was treated with furosemide, candesartan, and bucladesine sodium. 
The symptoms improved, but the dog presented with pulmonary oedema again, 5 days later. 
The severe MR and ruptured chordae tendineae rendered symptom management with 
medication ineffective; thus, MVR under cardiopulmonary bypass was recommended.  
General anesthesia36 and surgery were performed in the same manner for all dogs. 
Preanesthetic medications included atropine sulfatea (0.025 mg/kg, IM), midazolamb (0.3 
mg/kg, IV), fentanylc (5 µg/kg, IV), and cefazolin sodiumd (20 mg/kg, IV). Each dog was 
then oxygenated with 100% oxygen, which was followed by face mask induction with 5% 
isofluranee and intubation with an endotracheal tube (internal diameter, 4 to 7 mm). 
Anesthesia was maintained with 2% to 3% isoflurane in oxygen at 1.5 L/min. During CPB, 
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anesthesia was maintained by CRI of fentanylc (0.4 µg/kg/min, IV) and propofolf (0.2 
mg/kg/min, IV). 
   During the surgery, heart rate, respiratory rate, rectal temperature, esophageal 
temperature, arterial oxygen saturation, end-tidal CO2, and isoflurane concentration were 
continuously monitored by use of a physiologic monitor system.g The right femoral artery 
was catheterized for measurement of systolic, diastolic, and mean arterial blood pressures, 
and the femoral vein was catheterized for measurement of central venous pressure, both with 
a 22-gauge indwelling catheter. Complete blood count, Hct, total protein concentration, 
activated clotting time, and arterial blood gases were determined as necessary by use of 
blood samples obtained via the femoral artery catheter. A urinary catheter was placed to 
monitor urine volume. Cardiopulmonary bypass was provided by a heart-lung machineh 
with an extracorporeal circuit, 0.5-m2 oxygenator, and heat exchanger.i The CPB circuit 
was filled with 20% D-mannitolj (5 mL/kg), 7% sodium bicarbonatek (2 mL/kg), heparin 
sodiuml (500 U), and acetate Ringer's solutionm (120 to 170 mL). Fifty milliliters of whole 
blood was replaced with priming solution in dogs weighing < 4 kg. After a neck incision, the 
left carotid artery and external jugular vein were separated and secured with 3–0 nylon 
sutures. Next, a left thoracotomy was performed in the fourth or fifth intercostal space after 
intercostal nerve block with bupivacaine hydrochloride. To place a catheter for cardioplegic 
infusion, the aortic root was elevated and a purse-string suture was applied with a 5–0 
polyvinylidene fluoride suture.o Subsequently, heparin sodium (200 U/kg, IV) was 
administered. After 3 minutes, activated clotting time was measured with an analyzerp and 
confirmed to be > 300 seconds. An arterial CPB cannulaq was inserted into the carotid 
 8 
artery in a proximal direction. The arterial line of the CPB circuit was connected to the 
carotid artery with a CPB cannula. The venous cannular for blood withdrawal was inserted 
into the right atrium via the left jugular vein and connected to the CPB circuit. A 5F aortic 
root catheter was inserted at the site of the purse-string suture on the left lateral aspect of 
ascending aorta. After air was removed from the CPB circuit, partial CPB was initiated and 
the patient's body temperature was lowered to 30°C (86°F). Blood flow was controlled at 70 
to 100 mL/kg/min (31.8 to 45.5 mL/lb/min) by use of the CPB pump. At this time, the 
anesthetic was switched from isoflurane inhalation to IV administration of fentanyl and 
propofol. The aorta was occluded with an arterial clamp proximal to the brachiocephalic 
trunk, and cardioplegic solutions (10 mL/kg [4.5 mL/lb]; cooled to ≤ 4C; Na+, 120 mEq/L; 
K+, 20 mEq/L; Cl+, 160.4 mEq/L; Mg2+, 32.0 mEq/L; Ca2+, 2.4 mEq/L; and HCO3, 10 
mEq/L) was immediately and rapidly infused into the left and right coronary arteries via the 
aortic root to produce cardioplegia. The cardioplegic solution was infused every 20 minutes. 
During CPB, arterial and venous blood pressure, oxygen saturation, and arterial and venous 
blood gases were monitored. 
We approached the left atrium through a fourth intercostal thoracotomy and incised 
left auricle to approach to the mitral valve. Chordal replacement and semicircular suture 
annuloplasty were performed for mitral repair (Fig. 2). Artificial chordae tendineae 
comprising expanded polytetrafluoroethylene (ePTFE) were sutured to the septal mitral 
valve and papillary muscle. The lengths of the artificial chordae were adjusted to match the 
level of the mitral annulus. Circumferential suture annuloplasty was performed to reduce the 
size of the mitral orifice (Fig. 2). The mitral annulus was measured and plicated to provide 
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good coaptation. ePTFE (CV-6, Gore-Tex®, Tokyo, Japan) and prolene (5-0 prolene, 
Ethicon, Tokyo, Japan) sutures were used for chordal replacement and suture annuloplasty, 
respectively. 
The left atrium was closed with simple-interrupted and continuous 5–0 sutures. After 
closing the left atrium, the aortic clamp was released, and spontaneous sinus rhythm was 
observed. If ventricular fibrillation was observed, a defibrillator was used at 10 to 30 J. The 
duration of cardioplegia was 60 to 95 minutes. At the return of sinus rhythm, a dobutaminev 
CRI was started (1 to 5 µg/kg/min), if needed. The body temperature was recovered to 37°C, 
and the CPB flow was gradually reduced before being completely shut down. Anesthesia 
was switched to maintenance with isoflurane inhalation. 
  After recovery from CPB, the catheter for cardioplegic infusion was removed from the 
aorta. The catheters were removed from the jugular vein and carotid artery. The carotid 
artery and jugular vein were closed with a continuous pattern by use of 7–0 suture material. 
The cervical wound was closed with a simple continous pattern by use of 3–0 nylon. After 
the removal of catheters, protamine sulfate (6 mg/kg, IV) was administered over 30 minutes. 
Then, a thoracostomy tube was placed and the thorax was closed routinely after confirming 
that activated clotting time was < 200 seconds. The patients regained spontaneous 
respiration and reflexes 2 to 3 hours after the end of surgery. Isoflurane inhalation was 
discontinued, and the endotracheal tube was removed. The total duration of anesthesia was 4 
to 6 hours. After removal of the endotracheal tube, the patients were maintained in a cage 
filled with O2 (25% to 35%) for 12 to 24 hours. Dalteparin sodiumx (25 to 50 U/kg, SC) 
was administered when chest drainage fluid was reduced to a rate of < 1 to 2 mL/h. The 
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chest tube was removed 24 h after surgery. Cefazolin sodiumd (20 mg/kg, IV, q 8 h) was 
administered for 7 days. Laboratory tests were performed every day until discharge. Ozagrel 
hydrochloridey (10 mg/kg, PO, q 12 h), a thromboxane A2 synthase inhibitor, was 
administered for 1 month after surgery 
The dog was discharged, and the following changes were noted after 1 month: cardiac 
murmur (grade I), LA/Ao (1.5), VHS (10.2 v) (Fig. 3), normalised left ventricular end 
diastolic diameter (2.22), and plasma ANP concentration (86 pg/mL). Medication was 
discontinued, and the cardiac condition remained stable for 5 years after surgery. Five years 
after surgery, the MR had worsened due to ruptured native chordae tendineae of the mural 
mitral leaflet. 
 
Case 2: An 11-year-old male Shih Tzu weighing 4.6 kg with respiratory distress was 
admitted for emergency treatment of refractory pulmonary oedema caused by MR. Clinical 
examination identified a grade V systolic murmur over the mitral area. Plasma ANP was 154 
pg/mL. A thoracic radiograph showed cardiac enlargement (VHS 13.1 v) and pulmonary 
oedema. Two-dimensional echocardiography showed mitral valve prolapse, ruptured 
chordae tendineae, and an enlarged left atrium (LA/Ao: 2.8). The fractional shortening was 
49%, and the normalised, left ventricular end diastolic diameter was 2.68. Colour flow 
Doppler examination revealed severe MR. 
The dog was treated with furosemide (2 mg/kg, qid), candesartan (0.5 mg/kg, sid), 
pimobendan (0.1 mg/kg, sid), and bucladesine (0.02 mg/kg/min, CRI). However, the dog did 
not respond well. With owner consent, MVR was performed on day 27 of hospitalisation. 
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The surgical procedures were the same as for Case 1. 
One month after surgery, the cardiac murmur was grade II; LA/Ao, 1.6; VHS, 11.5 v; 
and plasma ANP concentration, 104 pg/mL. However, because of moderate residual MR, 
candesartan (0.5 mg/kg/day) was continued. Two years after surgery, the dog presented with 
premature ventricular contractions, congestive heart failure, worsened MR, and mitral 
annular dilatation; torasemide treatment (0.2–0.6 mg/kg/day) was started. Three years after 
surgery, the dog died due to pulmonary oedema. Post-mortem examination showed that the 
annular plication suture was partially detached from the mitral valve circumference (Fig. 4). 
 
Case 3: An 8-year-old male Maltese weighing 3.85 kg with respiratory distress was admitted 
for recurring pulmonary oedema caused by MR. Clinical examination identified a grade IV 
systolic murmur over the mitral area. Thoracic radiographs showed mild cardiac 
enlargement with a VHS of 11.4 v and pulmonary oedema. The plasma ANP concentration 
was elevated (219 pg/mL). Two-dimensional echocardiography showed mitral valve 
prolapse and ruptured chordae tendineae; however, the left atrium was not enlarged (LA/Ao: 
1.3). Colour flow Doppler examination revealed severe MR. The dog was treated with 
candesartan (0.5 mg/kg, sid), torasemide (0.3 mg/kg, bid), and bucladesine (0.02 mg/kg/min, 
CRI). Eleven days after hospitalisation, the dog recovered from the pulmonary oedema, but 
the owner desired that MVR surgery be performed. The surgery was conducted in a manner 
similar to that in the previous 2 cases.  
No residual MR was observed after surgery. One month after the surgery, the 
following changes were noted: cardiac murmur (disappeared), LA/Ao (1.3), VHS (10.2 v), 
 12 
and plasma ANP (96 pg/mL). At present (6 years after surgery), the dog is not receiving any 
cardiac medication and has not shown any clinical symptoms. 
 
2.1.3 Discussion 
 
Favourable long-term (5-year) outcomes were observed in 2 dogs; 1 experienced 
worsening MR and heart failure 3 years post surgery. Serres and others (2007) reported that 
the median survival time for dogs with International Small Animal Cardiac Health Council 
(IASCHC) class III and chordae tendineae rupture was 191 days.2 Although the medical 
treatment used in these three cases was unorthodox, these 3 dogs had severe mitral 
regurgitation with chordae tendineae rupture and these dogs were classified in ISACHC 
class III. So, the prognosis of these dogs would be poor, but surgical treatment may be 
associated with longer life expectancy. MVR and mitral valve replacement have been 
performed successfully in different-sized dogs with MR, including small-breed dogs, 7, 8 
indicating that MVR is an effective treatment option for MR in dogs.  
Here, chordal replacement was performed at the site of the chordal rupture, and MVR 
was performed using semicircular suture annuloplasty. The artificial chordae did not rupture 
in any of the dogs, suggesting that chordal replacement with ePTFE is as effective in dogs7, 
37 as in humans.38, 39, 40, 41 Chordal rupture—associated with the mural leaflet 
(unoperated)—occurred after 4 years in Case 1, causing a deteriorating clinical condition 
and increased MR. Thus, chordal replacement with ePTFE on the septal and mural leaflets 
may be required to prevent increasing MR due to native chordal rupture. 
 13 
Annuloplasty was performed with a mitral valve plication suture around the mitral 
valve. In Case 2, the suture detached, resulting in increased MR. It persisted unchanged in 
the other 2 dogs. Recurrent annular dilatation may be due to technical error, as a steep 
learning curve is expected.42, 43 Aybeck et al. also reported significant and progressive 
postoperative mitral annular dilatation associated with suture annuloplasty44. Therefore, 
based on these reports, a prosthetic ring was used during annuloplasty, rather than suture 
annuloplasty, in the subsequent patients. In contrast to suture annuloplasty, prosthetic ring 
annuloplasty may provide reproducible long-term results, as observed in humans38 and dogs7, 
9. Performing circumferential annuloplasty in dogs with MR could also reduce the amount of 
MR7, 9, 45. In human medicine, prosthetic ring annuloplasty is considered the gold standard 
technique for mitral repair due to its reproducibility and excellent long-term results44. 
Prosthetic rings also allow optimal annular stabilisation and systolic shape presentation but 
with some functional disadvantages46, 47, 48. Moreover, intracardiac prosthetic material is a 
potential site of haemolysis or thrombosis, while suture annuloplasty is free of these 
potential sequelae. The selection of the annuloplasty technique remains controversial; the 
most effective option in dogs needs to be investigated further.  
    Chordal replacement and circumferential annuloplasty were performed in 8 dogs with 
severe MR during the same period. Four dogs survived perioperative periods, but we could 
not follow one dog after discharge from our hospital. Four dogs died in perioperative periods. 
The causes of death were bleeding, worsening of pulmonary hypertension, ventricular 
fibrillation after weaning of CPB and low output syndrome after CPB. Although, currently 
the survival rate in perioperative period is improving9, the survival rate of this surgery is 
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about 90%. This is not satisfying result. Therefore, further study to improve the success rate 
of this surgery is needed. 
 
 
Section 2 
Intra- and Post-operative complications in 47 dogs that 
underwent mitral valve repair 
 
2.2.1 Introduction 
Section 1 shows that mitral valve repair is an effective treatment option for dogs with MR. 
However, the survival rate of mitral valve surgery is currently unsatisfactory. 
Cardiopulmonary bypass surgery can sometimes cause postoperative multi-system 
dysfunction of the renal, pulmonary, nervous, hepatic, and myocardial systems, as well as 
other life-threatening complications after surgery.4- 6 At our institution, various 
complications are observed after cardiopulmonary bypass surgery. The success rate of this 
surgery must be improved by preventing complications. In human medicine, prophylactic 
treatments are provided to reduce complications after cardiac surgery. However, there are 
only few reports regarding the complications of open-heart surgery with cardiopulmonary 
bypass in dogs. Investigating the types and incidence rates of complications can help 
identify problems in the perioperative period; this can improve the survival rate of mitral 
valve repair. The aim of this study was to investigate the complications of cardiac surgery 
using cardiopulmonary bypass in dogs to improve the survival rate. 
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2.2.2 Materials and Methods 
To assess the incidence of intra- and postoperative complications, we retrospectively 
reviewed 47 cases of dogs that underwent MVP with CPB at the Nihon University Animal 
Medical Center between August 2006 and September 2007. Mitral valve repair was 
performed as described in Chapter 2. We retrospectively investigated the incidence and 
causes of post-operative mortality and morbidity. 
 
2.2.3 Results 
Forty-seven dogs [22 males and 25 females, age: 62–175 (123±25) months, bodyweight: 
1.8–13.5 (5.7±3.0) kg] were enrolled. (Table 1) The mean age of the 10 dogs that died 
within 4 months of surgery was 140±21 (range: 115–175) months, which was significantly 
higher than the age of dogs that survived beyond 4 months post-surgery [119±25 (range: 62–
157) months]. The 4-month postoperative mortality rate was 29% for dogs aged 10 years or 
older and 11% for those younger than 10 years. The causes of death were surgical technical 
problems (2 cases), thrombosis (4 cases), pancreatitis (2 cases), pulmonary hypertension (1 
case), and unknown (1 case). Of the 37 subjects that survived beyond 4 months, 4 had 
postoperative complications (i.e., 1 case each of thrombotic cerebral infarction, pulmonary 
infarction, cerebellar infarction, and aspiration pneumonitis). 
 
2.2.3 Discussion 
Cardiac surgery using cardiopulmonary bypass can cause various complications, such as 
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renal, pulmonary, nervous, hepatic, and digestive organ, as well as myocardial 
dysfunction4-6. In this study, the main cause of mortality after mitral valve repair in dogs was 
related to thrombosis, followed by pancreatitis.  
Thrombus formation (including those in the left atrium) was observed in 12 subjects, and 
was the most frequent cause of postoperative complications and/or death. There appeared to 
be various causes of thrombosis associated with extracorporeal cardiovascular surgery, such 
as detachment of endothelial cells by grasping with forceps, foreign substances such as 
artificial chordae tendineae left inside the heart, and use of heparin, protamine, or proteolytic 
enzyme inhibitors. Griffith et al. reported that systemic thromboembolism was a main cause 
of post-operative mortality in dogs who had undergone mitral valve repair.49 These results 
suggest that preventing thrombus formation is important for the success of mitral valve 
repair with cardiopulmonary bypass. 
 The second most frequent cause of postoperative complications was related to 
inflammation. A strong systemic inflammatory response occurs due to the release of 
mediators caused by contact with blood and the extracorporeal surface during CPB, such 
myocardial ischemia reperfusion secondary to aortic cross-clamping, endotoxemia, and 
operative trauma.50, 51, 52 In this study, pancreatitis was the primary cause of mortality 
associated with inflammation. In human medicine, post-operative pancreatitis after cardiac 
valve surgery occurs frequently and affects the clinical outcome.53 Previous studies have 
reported that splanchnic ischemia, hypoperfusion, systemic inflammatory response, and 
nonpulsatile blood flow during cardiac surgery may cause pancreatic cellular injury; several 
risk factors have also been suggested.54-58 Same phenomenon may occur in dogs. However, 
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it does not become clear in veterinary clinical cases, yet. To reduce the incidence of 
inflammation and pancreatitis after cardiac surgery with CPB in dogs, understanding 
post-pump inflammatory responses and adopting countermeasures are as important in 
veterinary medicine as in human medicine. 
 
2.3 Conclusion 
In conclusion, MVR is an effective treatment option for dogs with MR. Chordal 
replacement with ePTFE is effective for dogs and provides long-term durability. However, 
mitral annuloplasty using prosthetic rings may be preferred over suture annuloplasty in dogs. 
Although the survival rate in the perioperative period is improving9, the results remain 
unsatisfactory. Thrombus formation (including those in the left atrium) is the most frequent 
cause of postoperative complications and/or death. The second most frequent reason for 
postoperative complications is related to inflammation. These results suggest that prevention 
of thrombosis and suppression of inflammation are important strategies for improving the 
surgical outcome of mitral valve repairs. Further study to improve the success rate is needed. 
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Chapter 3  
 
Plasma cytokine levels in dogs undergoing cardiopulmonary 
bypass 
 
3.1 Introduction 
Cardiac surgery using cardiopulmonary bypass (CPB) causes systemic 
inflammatory response syndrome (SIRS) in humans, characterized by the activation of the 
complement cascade and the production of cytokines, free radicals, and nitric oxide.10-12 
This so-called post-pump inflammatory response may induce postoperative multi-system 
dysfunction in the renal, pulmonary, nervous, hepatic, and myocardial systems,13-15 which 
may increase the morbidity and mortality of cardiac surgery.16 In fact, the results of the 
study in Chapter 1 suggested that inflammatory response after surgery may increase 
morbidity and mortality after mitral valve repair under cardiopulmonary bypass in dogs. 
The post-pump inflammatory response is triggered by various factors, including 
surgical trauma, endotoxin, reperfusion injury, and exposure of blood to the surface in the 
extracorporeal circuit.10, 11, 16 Several studies have reported elevation of pro-inflammatory 
(i.e., plasma interleukin-6 [IL-6], interleukin-8 [IL-8], and tissue necrosis factor-α [TNF-α]) 
and anti-inflammatory cytokines (i.e. interleukin-10 [IL-10]) after CPB in humans.12, 59 
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However, there is no report regarding the inflammatory response to CPB in dogs. The aim of 
this study was to clarify the inflammatory response to CPB in dogs by measuring pro- and 
anti-inflammatory cytokine levels, WBC counts, and CRP levels during and after CPB. 
3.2 Animals, materials and methods 
Cases 
Dogs that underwent mitral valve repair using CPB at Nihon University between April 2007 
and May 2009 were included in this study. All dogs weighed over 3 kg and did not have any 
evidence of congestive heart failure (CHF). Dogs with evidence of any systemic diseases 
were excluded from this study. 
Control 
Seven healthy female dogs based on physical examination were spayed and included in this 
study as the control group. 
Anesthesia and mitral valve repair 
Details of the anesthetic protocol and mitral valve repair procedure were previously 
described.60 Anesthesia and surgery were performed in the same manner in all dogs 
undergoing mitral valve repair. Cardiopulmonary bypass was performed with a 
cardiopulmonary bypass circuit. After induction of cardiac arrest, a mitral annuloplasty was 
performed, and the chordae tendineae were replaced with expanded polytetrafluoroethylene 
chordal prostheses. After closure of the left atrium and declamping to restart the heart, the 
thorax was closed. 
Dogs in the control group were induced by propofol, maintained by isoflurane, and 
underwent routine ovariohysterectomy. No complications were noted pre- or 
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postoperatively. 
Blood sampling 
Blood samples were collected preoperatively (pre), 5 minutes after administration of heparin 
(heparin +5), 5 minutes after clamping of the aorta (bypass +5), after resumption of the 
heartbeat (resume), 15 minutes after protamine sulfate administration (protamine +15), at 3 
hours (End of bypass [EB] +3hr), 6 hours (EB +6hr), 12 hours (EB +12hr), 24 hours (EB 
+24hr), and 48 hours after completion of CPB (EB +48hr). Blood samples were taken from 
an arterial catheter placed in the femoral artery from heparin +5 to EB +3hr and from the 
saphenous vein or jugular vein at pre and after EB +6hr.  
In the control group, blood samples were collected preoperatively (pre), at 5 minutes (OVH 
+0hr), 3 hours (OVH +3hr), 6 hours (OVH +6hr), and 24 hours after ovariohysterectomy 
(OVH +24hr). Blood samples were taken from the saphenous vein or jugular vein. 
C-reactive protein (CRP) measurements and white blood cell (WBC) counts 
 To obtain CRP measurements, blood samples were mixed with heparin and centrifuged at 
12,000 rpm for 120 seconds to isolate the plasma. Plasma concentrations of CRP were 
analyzed using an immunoserological testj (reference range, 0.05–20 mg/dL). The WBC 
counts were determined from blood mixed with ethylenediaminetetraacetic acid (EDTA) by 
an automated cell counterk. 
Cytokine measurements 
Blood samples for the measurement of cytokines were collected in EDTA tubes and 
centrifuged at 1000 g for 30 minutes at room temperature within 30 minutes after blood 
collection. The plasma was frozen and immediately stored below –20°C. Blood samples 
 21 
were thawed at room temperature before measurement. IL-6, IL-10, and TNF-α were 
analyzed using an enzyme-linked immunosorbent assay (ELISA) kitl.  
  
Statistical analysis 
Statistical analysis was performed with GraphPad Prism® Version 5.0 statistical software 
(GraphPad Software Inc.; San Diego, California, USA). Data was presented as mean ± 
standard deviation of the mean (SD). Changes in the parameters with time compared to 
baseline (pre) were analyzed using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons. Comparison of cytokine levels, CRP levels, and WBC 
counts between the cases and control group were analyzed using two-way ANOVA 
followed by Sidak’s multiple comparisons. A P value less than 0.05 indicated statistical 
significance. Pearson’s correlation coefficient test was performed to examine correlations 
between peak cytokine levels and the volume of transfusion. 
 
3.3 Results 
 During this study period, 63 dogs underwent mitral valve repair. Fifty-two dogs were 
excluded from this study because of pulmonary edema (n = 26), low body weight (<3 kg; n 
= 14), examiner absence (n = 9), congenital cardiac disease (n = 1), Chiari malformation (n 
= 1), and renal failure (n = 1). Eight of 63 dogs died during the hospital stay. The causes of 
death were as follows: intra-operative bleeding, sudden death, aspiration pneumonitis, acute 
renal failure, pancreatitis, and multiple organ failure. Thus, eleven dogs were included in 
this study. Clinical characteristics of the dogs are shown in Table 1. All surgeries were 
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successful, and the dogs were discharged within 2 weeks with no signs of complications 
(organ failure, severe inflammatory signs such as pneumonia or pancreatitis, low output 
syndrome, and thrombosis) or infections.  
1. Cytokine levels 
 IL-6 level increased significantly from protamine +15 (231 ± 284.4 pg/mL, P < 0.001) to 
peak values at EB +3hr (271 ± 179.8 pg/mL, P < 0.0001) in comparison with baseline (pre; 
3.96 ± 8.22 pg/mL). Thereafter, IL-6 levels progressively declined to pre-CPB levels by EB 
+48hr (Fig. 5A). Comparisons between groups with repeated measures ANOVA showed 
higher values in the cases compared with the control group (Time, P < 0.005; Groups, P < 
0.0001; Interaction, P < 0.05). With multiple comparisons, IL-6 levels of the cases at 
protamine +15, EB +3hr, and EB +6hr were significantly higher than those levels of the 
control group at OVH +0hr (13.5 ± 23.6 pg/mL), OVH +3hr (36.6 ± 32.1 pg/mL), and OVH 
+6hr (20.7 ± 25.3 pg/mL) (P < 0.001, P < 0.001, and P < 0.01, respectively) (Fig. 7A). 
 IL-10 levels increased from resume, peaked at protamine +15 (58.2 ± 65.2 pg/mL), and 
then decreased gradually (Fig. 5B). There were no significant differences among all time 
points in comparison with pre (3.71 ± 5.33 pg/mL). There were no significant differences 
between the cases and the control group (Fig. 7B).  
 TNF-α levels displayed a bimodal distribution, peaking at protamine +15 and EB +12hr 
(0.67 ± 1.63 pg/mL, 0.81 ± 1.99 pg/mL, respectively) (Fig. 5C). However, there were no 
significant differences among all time points in comparison with pre (0.2 ± 0.41 pg/mL). 
There were no significant differences between the cases and the control group (Fig. 7C). 
2. WBC count 
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 WBC counts decreased until bypass +5 and remained increased until the last time point at 
EB +48hr (Fig. 6A). WBC count at EB +24hr (27755 ± 10507/µL) was significantly higher 
than the control group at OVH +24hr (17411 ± 2565/µL) (P < 0.05) (Fig. 8A). 
3. CRP 
 CRP levels gradually increased from EB +3hr until the end of study at EB +48hr (Fig. 6B). 
There were no significant differences between the cases and the control group (Fig. 8B). 
4. Correlations between peak cytokine levels and the transfusion volume 
 The peak IL-6 concentration was significantly correlated with the transfusion volume (Fig. 
9, r = 0.719, r2 = 0.518, P < 0.05). However, there were no significant differences between 
peak IL-10 and TNF-α concentrations and total volume transfused. 
 
3.4 Discussion 
 CPB causes SIRS in humans, and cardiopulmonary bypass influences cytokine levels and 
complement activation during and after surgery.10, 11, 16 The present study showed that CPB 
significantly raised the plasma IL-6 level in dogs, as it does in humans.  
 IL-6 is involved in a wide variety of biological functions, especially in pro- and 
anti-inflammatory responses. It acts on B cells to induce differentiation into plasma cells, 
stimulates the release of hepatic proteins, and is involved in neutrophil-mediated 
ischemia/reperfusion injury.15 Therefore, the increase in plasma IL-6 measurements during 
and after CPB was probably a manifestation of an acute phase inflammatory response.  
 IL-10 is an anti-inflammatory cytokine that reduces neutrophil adhesion to activated 
endothelial cells. In infectious diseases and septic shock, IL-10 is synthesized later than 
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inflammatory cytokines in both T cells and monocytes, suggesting a regulatory role in the 
later phases of the immune response.61, 62 In contrast, although not statistically significant, 
the present study showed that IL-10 levels tended to increase earlier than IL-6. Risnes et 
al.63 reported a similar phenomenon and suggested that prostaglandin E2 and 
catecholamines may induce IL-10 secretion. However, the stimulatory mechanism of early 
IL-10 release occurring independently from systemic proinflammatory cytokine elevation 
remains unclear.  
 TNF-α produced by macrophages and monocytes is a proinflammatory cytokine that 
regulates the adhesiveness of leukocytes through the induction of adhesion molecules.64 The 
present study showed that TNF-α levels increased in a bimodal distribution. This result was 
similar to a previous report in humans.14 However, there were no significant differences 
between the values at different time points compared to those preoperatively, which may be 
due to the low sensitivity of the ELISA kit, as many of the results were below the detection 
limit. 
WBC counts and CRP levels were elevated after CPB compared with baseline, but 
none of the dogs showed signs of infection. Therefore, these changes may have been caused 
by the inflammatory response and surgical trauma. The WBC counts and CRP levels were 
increased for more than 2 days after CPB. This increase suggests that the inflammatory 
response caused by CPB and surgical trauma continues for at least 2 days. 
This study confirms that the levels of inflammatory biomarkers, IL-6, WBC 
counts, and CRP are elevated after CPB. In human medicine, it is known that the patients 
who undergo coronary artery surgery using CPB show more severe inflammatory response 
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after surgery than the patients without the use of CPB.65, 66 Therefore, it is thought that CPB 
induces an inflammatory response. In this study, IL-6 levels and WBC counts after CPB 
were significantly higher than the control group. This result shows that CPB may induce an 
inflammatory response in dogs as previously reported in humans. 
 Previous studies reported that transfusion and hemodilution enhanced the inflammatory 
response during CPB. 67, 68, 69 In this study, the volume of transfusion and IL-6 level had a 
significant correlation. Since most dogs that undergo mitral valve repair are small breed 
dogs, to reduce the amount of transfusion, it is important to minimize the priming volume, 
hemodilution, and blood loss. Frequent administration of cardioplegia causes hemodilution, 
which increases the number of transfusions. Minimizing the cardiac arrest time may also 
reduce the inflammatory response.  
 IL-6 is associated with postoperative renal, lung, and nerve dysfunction and myocardial 
injury.15,70,71 In canine systemic inflammatory syndrome and sepsis, plasma IL-6 
concentration was shown to be a predictor of outcomes.72 Therefore, hypercytokinemia 
facilitates SIRS and may worsen the condition of dogs after cardiac surgery.  
 Previous studies have demonstrated that increased IL-6 and CRP levels may contribute to 
myocardial dysfunction, lung inflammation, and intestinal dysfunction during various acute 
inflammatory conditions.15, 70, 71 In this study, all dogs were discharged as planned without 
any complications. However, about 7% of the dogs undergoing mitral valve repair have died 
after surgery in our institution.60 The CPB-induced systemic inflammatory response 
described in this study may increase mortality or be a trigger for postoperative complications. 
Therefore, countermeasures against the inflammatory response after CPB, such as 
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improvement of the CPB circuit, administration of steroids or protease inhibitors, reduction 
of the cardiac arrest time, and minimization of hemodilution, transfusion, and priming 
volume or development of other radicar treatment for mitral valve insufficiency without 
cardiopulmonary bypass (e.g. transcatheter valve replacement or transcatheter mitral repair) 
may be required to improve patient outcomes.  
3.5 Conclusion 
 CPB induced IL-6 release that triggered a postoperative inflammatory response which 
included elevations in WBC. Such an inflammatory response after cardiac surgery may 
cause acute lung injury, myocardial dysfunction, renal failure, and multiple organ failure, 
which ultimately may increase postoperative mortality and morbidity. Therefore, 
countermeasures against the inflammatory response after CPB or development of other 
radical treatment for mitral valve insufficiency without cardiopulmonary bypass (e.g. 
transcatheter valve replacement or transcatheter mitral repair) may be required to improve 
patient outcomes. 
 
3.6 Study Limitations 
 Inflammatory pathways not mediated by cytokines (e.g., complement and leukocytes) were 
not directly examined. Open heart surgery may be more invasive than ovariohysterectomy. 
Therefore, the difference in cytokine levels and WBC counts might be influenced by the 
differences in surgery-related stress between open heart surgery and ovariohysterectomy. 
 This study excluded dogs with CHF or systemic diseases because we wanted to determine 
the inflammatory response to CPB in dogs. The number of dogs included in this study was 
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small, but all included cases survived and did not show any complications (organ failure, 
severe inflammatory signs such as pneumonia or pancreatitis, and thrombosis). Therefore, 
we could not confirm whether hypercytokinemia affected the outcome of the dogs that 
underwent CPB. In the future, a larger study is needed to confirm whether hypercytokinemia 
after CPB contributes to organ dysfunction.  
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Chapter 4 
 
Preparation of an autologous heart valve with a stent (stent biovalve) 
using the stent evertion method 
 
4.1 Introduction 
The results of previous chapter reveal that countermeasures against the inflammatory 
response after CPB or development of other radical treatment for mitral valve insufficiency 
without cardiopulmonary bypass (e.g. transcatheter valve replacement or transcatheter mitral 
repair) may be required to improve patient outcomes. Since 2002,17 the less invasive 
transcatheter aortic valve implantation (TAVI) has been introduced for inoperable and 
high-risk patients. Recently, with technological advancements, the clinical application of 
TAVI has extended to intermediate-risk patients.18 TAVI is expected to evolve further and 
become more commonly used in the future. Transcatheter valve replacement of 
atrioventricular valves (mitral valve and tricuspid valve) such as valve in the mitral ring 
implantation or in annuloplasty ring implantation were clinically performed to the 
re-operative patient. Transcatheter replacement of the native atrioventricular valves is not a 
clinical reality yet due to several technical problems arising from the large size and irregular 
shape of the annulus, potentially resulting in complications with prosthesis fixation and 
perivalvular leak. Nonetheless, two acute animal studies have been published pioneering 
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feasibility of transcatheter valve implantation in the native mitral and tricuspid position 
using a custom-made nitinol stent19, 20. However, using a bioprosthetic valve for TVR has 
certain disadvantages, since it undergoes progressive degeneration and calcification as it 
contains no living cells.21, 22 To overcome these limitations, living heart valves—created by 
tissue engineering—have been under development. Some heart valves created by tissue 
engineering have been successfully implanted in animals.23, 24 However, these valves require 
complicated cell management protocols with cell culture in bioreactors under strictly sterile 
conditions; this procedure is time-consuming and expensive. 
We have previously developed autologous prosthetic tissues by using the “in-body 
tissue architecture (IBTA)” technology, which is a novel and practical approach for 
regenerative medicine based on the tissue encapsulation phenomenon of foreign materials in 
living bodies.25 This technology involves the use of living bodies as a reactor, and does not 
need expensive facilities or complicated manipulations. We have reported the construction 
of completely autologous tri-leaflet heart valves, named Biovalves, prepared using this 
technology, 26-29 which may resolve the abovementioned problems encountered with 
bioprosthetic valves. In fact, Biovalves have been demonstrated to have excellent valve 
function and histological changes when implanted as a pulmonary valve in a beagle model 
and an aortic valve in a goat model.30, 31 In these Biovalves, leaflet formation occurs by 
tissue ingrowth into small apertures in the preparation molds from the connective tissues 
surrounding the molds. During the encapsulation process, the conduit portion of the 
Biovalve is completely formed within approximately 4 weeks of embedding, similar to the 
Biotubes, which are autologous vascular grafts from IBTA. However, because tissue 
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migration into a small aperture is slow in general, leaflet formation in the Biovalve required 
a longer time than that required for conduit formation. 
In this study, to further improve the Biovalve design and to adapt it for transcatheter 
valve replacement, we attempted to combine the Biovalve design with a self-expandable 
nitinol stent to construct a “Stent-Biovalve”. The preparation mold was designed based on a 
novel concept, in which the leaflet tissue was formed on the outer side of the mold; the 
tri-leaflet-shaped valve was obtained by finally everting the stent such that the leaflet tissue 
existed inside surface of the stent. The valvular function of the Stent-Biovalve was 
examined by using an in vitro circulation circuit. Finally the Stent-Biovalve was implanted 
in the mitral position in a beagle dog. 
 
4.2 Materials and Methods 
Animal Studies 
Studies were performed in accordance with the “Guide for the Care and Use of 
Laboratory Animals” published by the US National Institutes of Health (NIH Publication No. 
85-23, revised 1996) under a protocol approved by the National Cerebral and Cardiovascular 
Center Research Institute Committee (No. 12002). 
 
Mold Assembling 
Two kind of stents used were self-expandable (diameter, 14 mm; length, 15 mm or 
diameter, 20 mm; length, 30 mm), obtained from shape re-memory of E-LUMINEXX 
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(diameter, 12 mm; length, 100 mm; Bard, Karlsruhe, Germany) by Piolax Medical Devices 
(Yokohama, Japan) and cutting. 
The mold for the Stent-Biovalve was obtained by assembling the stent, a specially 
designed column-shaped acrylic part (outer diameter, 14 mm; length, 32 mm for 14 
mm-sized stent, and outer diameter, 20 mm; length, 46 mm for 20 mm-sized stent), and 
cylinder-shaped acrylic part (outer diameter, 17 mm; length, 18 mm for 14 mm-sized stent, 
and outer diameter, 23 mm; length, 34 mm for 20 mm-sized stent) with three slits (width, 1 
mm; length, 10 mm for 14 mm-sized stent, and width, 1 mm; length, 15 mm for 20 
mm-sized stent). All acrylic parts were prepared using a 3D printer (CONNEX 260, Objet, 
Rehovot, Israel). After gently everting the stent in ice water, it was mounted on the 
column-shaped acrylic part and then covered with the cylinder-shaped part for the final 
mold. 
 
Preparation of Stent-Biovalves 
A beagle dog (age, 1 year; body weight, 10 kg) under general anesthesia induced by 
intramuscular injection of ketamine (20 mg/kg), or a goat (age, 1 year; body weight, 50 kg) 
under general anesthesia induced with 10 mg/kg of ketamine and maintained with 1–3% 
isoflurane was used for the Stent-Biovalve preparation. After 4 weeks of mold embedding in 
the abdominal subcutaneous pouches of each animal, the implants—which were completely 
encapsulated with connective tissue—were harvested. The fragile, irregular, and redundant 
tissues around the developed tubular tissue were gently cut, and the impregnated parts were 
removed from both the ends of the developed capsular tissue. The acrylic cylinder- and 
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column-shaped parts were removed. The stent, now embedded in connective tissue, also 
showed 3 flaps of membranous connective tissue on its outer surface. The stent was then 
everted to its original form in ice water to obtain the Stent-Biovalve, with a tri-leaflet valve 
on its inner surface.  
 
Measurement of Burst Strength 
The burst strength of the leaflet tissues of Stent-Biovalve was determined by using a 
specially designed apparatus. The specimens were fixed on a sample holder with a hole 
(diameter, 2 mm) at its center. Saline solution was introduced into this apparatus at a rate of 
50 mmHg/s. The burst strength was determined by measuring the water pressure at the 
instant of the tissue rupture using a pressure transducer (N5901; Nihon Denki Sanei, Inc., 
Tokyo, Japan). 
 
Histological Evaluation 
Some parts of the leaflet of Stent-Biovalve were fixed in 10% formalin solution and 
embedded in paraffin. Then leaflet sections were cut into pieces 3-5µm thick for 
hematoxyline and eosin staining. In addition, the histological sections were stained with 
masson trichrome stain. The composition cell was evaluated and the wall thickness of the 
TEVGs was measured by microscopic examination of cross sections. 
 
Mechanical test 
  Measurement of the connective strength between leaflet and stent of Stent-Biovalve were 
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performed by use of a uniaxial tensile-testing apparatus (Rheoner II; Yamaden, Tokyo, 
Japan). The connective strength between native aortic valve and conduit of goat were also 
measured by same way. Each sample was fixed in a sample folder that was specially 
designed by use of a 3D printer (Projet HD3000; 3D Systems, Rock Hill, SC, USA). The 
testing speed was 0.05 mm/s until failure, i.e., tissue rupture. Ultimate tensile strength was 
calculated from the stress-strain curves. 
 
In Vitro Valve Function 
Valve function was examined using a pulsatile circulation circuit (LaboHeart NCVC, 
IWAKI; working fluid, 0.9% saline; mean arterial pressure, 100 mmHg; mean flow rate, 5–6 
L/min, Fig. 2). The flow rate, left ventricular pressure, and aortic pressure were measured 
using an ultrasonic flow meter and pressure meter. The regurgitant ratio and mean flow rate 
at every 10 bpm from 70 to 120 pulsatile rates were evaluated.  
 
Implantation of the Stent-Biovalve in the mitral position in a beagle dog 
A beagle dog (age, 1 year; body weight, 10 kg), under general anesthesia induced by 
intramuscular injection of ketamine (20 mg/kg) and maintained with 1–3% isoflurane, was 
used for the Stent-Biovalve implantation. We approached the left atrium through fourth 
intercostal thoracotomy. The Stent-Biovalve was set into the self-build delivery catheter. A 
purse-string suture was placed at the left atrium. The position of the mitral annulus was 
confirmed with angiography. The Stent-Biovalve was implanted in the mitral position by 
using a delivery catheter through the left atrium. After the chest was closed, the movement 
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of the Stent-Biovalve at the mitral position was confirmed by echocardiography. 
 
4.3 Results 
Preparation of Stent-Biovalves 
The two different sized assembled molds (outer diameter of stents, 14 or 20 mm; Fig. 
10A) that were embedded in the subcutaneous pouches of the beagle or the goat for 4 weeks 
showed complete encapsulation with autologous connective tissue (Fig. 10B). The implants 
could be easily harvested because the developed capsulated tissues and the surrounding 
subcutaneous tissues were connected only by very fragile, irregular, and redundant tissues, 
which could be easily removed. The capsulated tissues were dissected to remain the tissue 
for the leaflets (Fig. 10C). The molds could be smoothly removed from both ends of the 
implant because there was no adhesion between the molds and the tissues covering the stent 
(Fig. 10D). The leaflet tissues were strongly fixed at the three commissures. The stents were 
iced and then inverted inside out. The tissue flaps, which originally existed outside the stent, 
were thereby converted to inner leaflets; the Stent-Biovalves were thus completely prepared 
(Fig. 10E). During the inversion, no or little damage occurred to the leaflet tissues and to the 
connecting tissues between the leaflet and the stent.  
Burst Strength 
The burst strength of the leaflet was over 7600 mmHg. Two sized Stent-Biovalves 
with a sufficient coaptation area were thus obtained with outer diameter of 14 mm from a 
beagle or 20 mm from a goat (Fig. 11). 
Histological evaluation 
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The valve leaflets of Stent-Biovalve mainly consisted of collagen fibers and fibroblasts (Fig. 
12). The thickness of the valve leaflet was 579.9 ± 8.2 µm. 
Mechanical results 
To evaluate the connective strength between Biovalve leaflet and stent, the tensile strength 
of the Biovalve leaflet and stent was measured (Fig. 13). The connective strength between 
Biovalve leaflets and stent was comparable to between aortic valve and conduit of goats. 
The mean values of ultimate tensile strength in each sample were as follows, Biovalve 
leaflet-stent: 833.8±215.5 gf; aortic valve- conduit of goat: 949.7±186.1 gf. 
In vitro valve function 
The movement of the leaflets in a pulsatile flow circuit (Fig. 14) was examined using 
videography. The Stent-Biovalve leaflets closed rapidly and tightly in synchronization with 
the backward flow in the diastolic phase. In the transition phase of the flow direction, the 
valve opened smoothly and the aperture ratio of the valve was 89% (Fig. 15A), and 
coaptation of valve leaflets was optimal (Fig. 15B). 
Figure 5C shows the flow rate waveforms of the Stent-Biovalve at 70 bpm. 
Regurgitation in the diastolic phase was almost completely prevented. The mean flow rate 
was approximately 5–6 L/min (Fig. 16A), and the regurgitation ratio was approximately 4% 
for each heart rate tested (Fig. 16B). 
Implantation of the Stent-Biovalve in the mitral position in a beagle dog 
Implantation of the Stent-Biovalve in the mitral position was performed smoothly and easily 
by using original delivery catheter (Figure 17) within 1 hour. The Stent-Biovalve leaflets 
closed and opened smoothly. Although little paravalvular leakage was confirmed, there was 
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no regurgitant color flow through the Stent-Biovalve. (Figure 18) 
 
4.4 Discussion 
Here, we report the successful development of novel construction method for a 
Stent-Biovalve with robust valve leaflets and favorable in vitro function.  
In the previously reported design for Biovalves, the molds were designed such that 
valve leaflets were formed by connective tissue penetrating the apertures in the preparation 
molds. However, such tissue ingrowth was slow; the formation of the valve leaflets therefore 
required a long duration and was not always robust.  
In the present technique, the structure of the new molds for the Stent-Biovalve 
ensured successful formation of three valve leaflets, with broad flaps available. The key 
point of this mold design was that the outer circumferential connective tissue was used to 
form each valve leaflet. Typically, in a tri-leaflet valve with a diameter of 14 mm, the 
horizontal leaflet length for adequate coaptation in the closed valve is 14 mm. Using the 
present method, the leaflet was formed along the acrylic cylinder-shaped part, which had a 
length of 17 mm, on the outer side of the stent that had a diameter of 14 mm. Thus, the 
formed leaflet had a length of 17 mm, which is approximately 1.2 times longer than that 
required for definitive coaptation. Since the area of the leaflet tissues was sufficient large, an 
extremely low regurgitation rate (~4%) was noted when testing in vitro valvular function, 
much lower than that noted for the previous Biovalve (type IV, regurgitation rate 20%). 
Moreover, since the valve leaflets were technically formed in the opening state, each 
valve leaflet opened smoothly in the systolic phase, resulting in a high aperture ratio of 89%. 
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In addition, the leaflet tissues were very robust because the tissues were originally formed as 
a conduit. In our previous Biovalve (type V), the burst strength of the tissue that was formed 
as a conduit (over 7600 mmHg) was over two times greater than that of the leaflet part (2900 
± 1300 mmHg); however, in the native aortic valve, high burst strength was obtained in both 
the conduit (over 7600 mmHg) and leaflet parts 6200 ± 1400 mmHg). The connective 
strength between Biovalve leaflet and stent was comparable to native aortic valve and 
conduit. Therefore, the strength of the leaflet tissue formed in this Stent-Biovalve was 
similar to that of the native valve tissue. 
In order to facilitate the use of the Stent-Biovalve in TVR, a self-expandable nitinol 
stent was chosen in this study, which is typically used for transcatheter aortic valve 
implantation (TAVI) (CoreValve, Medtronic Inc., Minneapolis, USA). 73 For transcatheter 
implantation, the CoreValve is crimped into a sheathed catheter under low temperature 
conditions.74 The valve leaflet for TAVI thus requires adequate durability and a strong tissue 
connection with the stent for successful crimping into the sheathed catheter. The 
Stent-Biovalves constructed in the present study showed favorable valve function even after 
eversion (inside out) under low temperature conditions (iced water). This handling exposed 
the valve leaflets to conditions that were more severe than crimping. Even after turning the 
stent inside out, the valve leaflets remained strongly connected with the stent (Fig. 1D), 
which did not tear apart even by pulling with forceps, as demonstrated in the type IV 
Biovalve, which was strongly attached to a scaffold material.29 Therefore, it is highly 
expected that the valve leaflets of the Stent-Biovalve would have sufficient durability and a 
robust tissue connection with the stent for crimping into a sheathed catheter for TAVI. 
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Recently, several studies reported that tissue engineered valved stents were 
successfully implanted as pulmonic valve in vivo.75-77 These materials may overcome the 
limitaions of bioprosthetic heart valve prostheses and may be expected further evolution to 
be applied to clinical use. However, these tissue-engineered valved stents require 
complicated cell management protocols with cell culture under strictly sterile conditions, 
and also require decellularized allografts or synthetic scaffold materials to seed autologous 
cells. In this study, autologous heart valve with stent (Stent-Biovalve) showed favorable 
valve function, without expensive facilities or complicated manipulations. Stent-Biovalve 
may overcome the limitations of bioprosthetic heart valve prostheses and have the advantage 
of other tissue engineered valved stents. 
In this study, the pulsatile circuit was designed for actual human aortic valve 
conditions (mean flow, 5 L/min; mean pressure, 100 mmHg; heart rate, 70–100 bpm); 
however, saline solution was selected as a working fluid. The kinetic viscosity of blood is 
4.4 × 10-6 m2/s, which is approximately 4 times that of saline solution (1.0 × 10-6 m2/s). Thus, 
our circuit did not approximate the viscosity of blood; however, it was considered that the 
present design achieved an adequate performance of valvular function for a future animal 
implantation study. 
Based on the American College of Cardiology/American Heart Association valvular 
guidelines 2006,18 the regurgitant fraction of the present Stent-Biovalve was much lower 
than the “mild” classification, in fact being present at “trace” levels. Yare et al. reported that 
75% of bioprosthetic valves used for TAVI showed trace to mild aortic regurgitation (AR) 
after implantation; however, such AR did not affect LV structure and function.78 Previous 
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biovalves were demonstrated to have favorable valve function and histological changes 
when used as heart valves in a beagle model30; further, biotubes created by in-body tissue 
architecture technology regenerated arteries within 3 months of implantation.79 Therefore, 
although the present evaluation of the Stent-Biovalve was performed in vitro, it is expected 
that this Stent-Biovalve with autologous valve leaflets will show more favorable function in 
vivo than in vitro.  Although only one pilot animal study was performed here, the 
Stent-Biovalve showed good valve function at the mitral position in the short study period. 
We expect that this Stent-Biovalve can be a good treatment device for canine chronic mitral 
valve disease. Future studies are expected to focus on the implantation of this 
Stent-Biovalve in animal models to confirm chronic valve function and durability in vivo.  
 
4.5 Conclusion 
We successfully developed a novel method for efficient construction of a robust, 
completely autologous heart valve eversion of a self-expandable stent, and named the 
resulting product the Stent-Biovalve. These Stent-Biovalves were obtained after only 4 
weeks of subcutaneous embedding in a beagle dog or a goat. Owing to the large and robust 
leaflet tissues that were developed in the open-form position, excellent in vitro valve 
function was achieved. As shown in the pilot model in this study, the Stent-Biovalve can be 
a novel treatment device for canine chronic mitral valve disease. Future studies are expected 
to focus on the implantation of this Stent-Biovalve in animal models to confirm chronic 
valve function and durability in vivo. 
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Chapter 5 
 
Conclusions 
 
Mitral regurgitation (MR) due to degenerative mitral valve disease is the most 
common heart disease in dogs, accounting for 75 to 80% of cardiac disease in dogs. Signs of 
progressive MR may be challenging to control with medication alone. In this thesis, the 
problems and effectiveness of mitral valve repair under cardiopulmonary bypass were 
revealed and autologous heart valves with stents were developed.  
Chapter 2 
Mitral valve repair under cardiopulmonary bypass was performed in three dogs with 
clinical signs associated with mitral regurgitation that were not controlled by medication. 
Mitral valve repair comprised circumferential annuloplasty and chordal replacement with 
expanded polytetrafluoroethylene. One dog died 2 years after surgery because of severe 
mitral regurgitation resulting from partial circumferential suture detachment. The others 
survived for over 5 years, but mild mitral valve stenosis persisted in one. The replaced 
chordae did not rupture in any dog. Mitral valve repair appears to be an effective treatment 
for mitral regurgitation in dogs. Chordal replacement with expanded polytetrafluoroethylene 
is a feasible technique, demonstrating long-term durability in dogs.  
Chordal replacement and circumferential annuloplasty were performed in 8 dogs with 
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severe MR during the same period. Four dogs died in perioperative periods. The causes of 
death were related to the surgical technique or drawbacks of using cardiopulmonary bypass. 
Although, currently the survival rate in perioperative period is improving (about 90%), this 
is not satisfying result. Thrombus formation (including those in the left atrium) was the most 
frequent cause of postoperative complication and/or death. The second most frequent reason 
for postoperative complications was related to inflammation. These results suggest that 
prevention of thrombosis and suppression of inflammation are important strategies for 
improving the surgical outcome of mitral valve repair. Further study to improve the success 
rate of this surgery is needed. 
Chapter 3 
We investigated the time course of pro- and anti-inflammatory cytokine levels during and 
after CPB and the correlation of the levels with variable parameters of CPB. The study 
group included 11 dogs that underwent mitral valve repair with CPB at Nihon University 
between April 2007 and May 2009, and the control group included 7 healthy dogs that 
underwent ovariohysterectomy. After CPB, plasma levels of IL-6, WBC counts, and CRP 
levels were significantly higher than preoperative levels, and IL-6 levels in the study group 
were significantly higher than those in the control group. Peak IL-6 level was significantly 
correlated with total blood administration. CPB induces a systemic inflammatory response 
in dogs. Such an inflammatory response after cardiac surgery ultimately may increase 
postoperative mortality and morbidity. These results demonstrated that to improve outcomes 
of the patients receiving surgical treatment for mitral valve insufficiency, countermeasures 
against the inflammatory response after CPB or development of other radical treatment for 
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mitral valve insufficiency without using cardiopulmonary bypass (e.g. transcatheter valve 
replacement or transcatheter mitral repair) were required. 
Chapter 4 
We designed a novel method for constructing an autologous heart valve with a stent, called a 
stent-biovalve. In constructing completely autologous heart valves, named biovalves, which 
used in-body tissue architecture technology, tissues for leaflets were formed via ingrowths 
into narrow apertures in the preparation molds, frequently leading to delayed or incomplete 
biovalve preparation. In this technique, self-expandable nitinol stents after everting were 
mounted on an acrylic column-shaped part and partially covered with an acrylic 
cylinder-shaped part with three slits. This assembled mold was placed into subcutaneous 
abdominal pouches in beagles or goats for 4 weeks. Upon removing the acrylic parts after 
harvesting and trimming of capsulated tissues, a tubular hollow structure with three 
pocket-flaps of membranous tissue rigidly fixed to the stent’s outer surface was obtained. 
Then, the stent was turned inside out to the original form, thus moving the pocket-flaps from 
outside to the inside. Stent-biovalves with a sufficient coaptation area were thus obtained 
with little tissue damage in all cases. The valve opened smoothly, and high aperture ratio 
was noted. This novel technique was thus highly effective in constructing a robust, 
completely autologous stent-biovalve with adequate valve function. As shown in the pilot 
model in this study, the Stent-Biovalve will show favorable valve function in vivo too. The 
Stent-Biovalve can be a novel treatment device for canine chronic mitral valve disease. 
Future studies are expected to focus on the implantation of this Stent-Biovalve in animal 
models to confirm chronic valve function and durability in vivo. 
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Age (month) 123 ± 25 Cavalier 11 
Sex (male: female) 22: 25 Shih-tzu 8 
Body weight (kg) 5.7 ± 3.0 Chihuahua 8 
ISACHC classification  Maltese 7 
Ia 1 Pomeranian 4 
Ib 2 Beagle 2 
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II 12 Other 7 
IIIa 25   
IIIb 7   
 
Table 1. Clinical characteristics of the dogs. 
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Table 
2 
Clinic
al characteristics of dogs undergoing cardiopulmonary bypass 
 
 
 
 
 
Sex (male:female) 6:5 
Age (months)  
  Mean 120.3 ± 18.8 
  Range 96–145 
Weight (kg)  
  Mean 7.3 ± 2.2 
  Range 3–10.7 
CPB duration (min)  
  Mean 166.3 ± 18.3 
  Range 112–200 
Cross-clamp time (min)  
  Mean 118.2 ± 10.1 
  Range 84–135 
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Fig. 1 Cardiovascular tissue engineering by in body tissue architecture technology (IBTA) 
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Fig 2. Procedure for circumferential annuloplasty. A double semicircular suture was 
place in the mitral annulus around the posterior leaflet. The suture was reinforced with 
pledgets at each commissure 
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Fig. 3 Thoracic radiography (Case 1) 
   A, B; Preoperative thoracic radiography, VHS=11v 
   C, D; Postoperative thoracic radiography, VHS=10.2 
   E, F; 5 years after surgery, VHS=12.4v 
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Fig 4. Post-mortem images from case 2. Stability of the artificial chordae (arrow) was 
confirmed. To the naked eye, the chordae were indistinguishable from the native 
chordae tendineae. The annular plication suture was partially detached from the mitral 
valve annulus (arrowhead). SMV, septal mitral leaflet; MMV, mural mitral leaflet; CC, 
cranial commissure 
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Fig. 5. Plasma cytokine levels before, during, and after CPB. IL-6 levels (A), IL-10 levels 
(B), and TNF-α levels (C) before, during, and after surgery.  
Points of collection are preoperatively (pre), 5 minutes after administration of heparin 
(heparin +5), 5 minutes after clamp of aorta (bypass +5), after resumption of the heartbeat 
(resume), 15 minutes after protamine sulfate administration (protamine +15), 3 hours after 
completion of CPB (EB +3hr), 6 hours after completion of CPB (EB +6hr), 12 hours after 
completion of CPB (EB +12hr), 24 hours after completion of CPB (EB +24hr), and at 48 
hours after completion of CPB (EB +48hr). Error bars indicate the standard deviation of the 
mean. * P < 0.05, ** P < 0.01, *** P < 0.005 and **** P < 0.0005 compared with 
preoperative levels (pre). 
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Fig. 6. White blood cell counts (A) and CRP concentrations (B) before, during, 
and after surgery. Points of collection are pre, heparin +5, bypass +5, resume, 
protamine +15, EB +3hr, EB +6hr, EB +12hr, EB +24hr, and EB +48hr (Please 
see text for additional details). Error bars indicate the standard deviation of the 
mean.  
* P < 0.05, ** P < 0.01, *** P < 0.005 and **** P < 0.0005 compared with 
preoperative levels (pre). 
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Fig. 7. Plasma cytokine levels of IL-6 (A), IL-10 (B), and TNF-α (C) in 
cardiopulmonary bypass cases (dogs underwent mitral valve repair) and the 
control group (dogs underwent ovariohysterectomy) before and after operation. 
** Significantly different between the cases and the control group (P < 0.01). 
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Fig. 8. White blood cell counts (A) and CRP concentrations (B) of cardiopulmonary bypass 
group and control group before and after operation. * P < 0.05 compared with the control 
group. 
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Fig. 9. Relationship between PCV-corrected peak IL-6 level and the transfusion volume  (r 
= 0.719, r2 = 0.518, P < 0.05). 
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Fig. 10 Preparation process of the Stent-Biovalve using the stent eversion method. A specially 
designed cylinder-shaped part, column-shaped part, and self-expandable nitinol stent (diameter, 14 
or 20 mm) were assembled to prepare molds for Stent-Biovalves (A). After 4 weeks of in vivo mold 
placement, the implants were completely encapsulated with robust connective tissue (B). After 
trimming the capsulated tissue the three leaflet parts were obtained (C). The cylinder and column 
parts were removed to create a patent hollow tube partially fixed with the stent (D). Each stent was 
iced and turned inside out again (E). The three pocket-flaps that were outside the stent now formed a 
tricuspid valve on the inner surface. 
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Fig. 11 The obtained Stent-Biovalves with diameter of 20 mm (A) and 14 mm (B). 
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Fig. 12 Schematics of mechanical tests. Sample was fixed in a sample folder () that was 
specially designed by use of a 3D printer.  
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Fig. 13 A pulsatile circulation circuit model designed for the evaluation of valve function. 
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Fig. 14 Histology of the leaflet of stent-biovalve stained with Hematoxylin and eosin 
staining (A) and Masson’s and trichrome staining (B). bar =100 mm. 
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Fig. 15. Macroscopic photos of the opening (A) and closing (B) form of the stent-biovalve in 
the circuit as shown in Figure 3. The pulsatile flow was 70 bpm, and the mean flow rate was 
5–6 L/min. The aperture ratio was 89%. Pulsatile flow waveform in a single cycle of the 
stent-biovalve. 
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Fig. 16. Mean flow rate (A) and regurgitation rate (B) at every 10 bpm from 70 to 120 bpm. 
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                Figure 17 Delivery catheter of the Stent-Biovalve 
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                                  Opening form            Closing form 
 
Figure 18 Echocardiographic images of the opening and closing form of the Stent-Biovalve 
in the mitral position 
 
 
 
 
 
 
 
 
 
